Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2022-04-22 Regulatory Filings
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Ultimovacs Receives Notice of Allowance on US Patent on Vaccine-Checkpoint Inhibitor Combinations
Regulatory Filings Classification · 100% confidence The document is a press release from Ultimovacs ASA announcing that they received a 'Notice of Allowance from the United States Patent and Trademarks Office (USPTO)' regarding a patent for their UV1 vaccine combinations. This announcement concerns intellectual property and legal/regulatory developments, specifically related to patent protection extension. This type of announcement, which is a specific regulatory or legal update that doesn't fit into standard financial reports (10-K, IR, ER), is best classified under the general 'Regulatory Filings' category (RNS) as it is a formal, non-financial disclosure to the market, or potentially LTR if it were about a lawsuit, but patent allowance is a positive legal event. Given the options, RNS serves as the best general regulatory announcement fallback for non-financial, non-management/board specific news. It is not a financial report, earnings release, or management change.
2022-04-22 English
Ultimovacs ASA - Share Option Program
Remuneration Information Classification · 99% confidence The document explicitly details the resolution by the Board of Directors to issue share options to employees under a long-term incentive program, following approval from the General Meeting. It specifies the number of options (480,000), the vesting schedule, the exercise price (NOK 83.46), and the extension of the life of previously granted options. This content directly relates to changes in the company's capital structure concerning employee incentives, which aligns best with the 'Capital/Financing Update' category (CAP). While it involves shares, it is not a general share issue (SHA) or a buyback (POS), but a specific financing/incentive mechanism.
2022-04-21 English
Ultimovacs ASA - Annual General Meeting held on 21 April 2022
AGM Information Classification · 100% confidence The document text explicitly states it is the "PROTOKOLL FRA ORDINÆR GENERALFORSAMLING I ULTIMOVACS ASA" (MINUTES OF THE ANNUAL GENERAL MEETING IN ULTIMOVACS ASA). It details the agenda, resolutions passed regarding the approval of the annual accounts, election of the board, remuneration, and authorizations granted by the meeting. This content is characteristic of the official record of an Annual General Meeting.
2022-04-21 Norwegian
Ultimovacs ASA - Annual General Meeting held on 21 April 2022
AGM Information Classification · 99% confidence The document explicitly states it concerns the 'Annual General Meeting held on 21 April 2022' for Ultimovacs ASA. It details the outcomes, specifically the re-election of all board members and the retirement of a deputy member. This content directly relates to the proceedings and outcomes of the AGM. Therefore, the appropriate classification is AGM Information (AGM-R). The document length is short, but it contains the substance of the meeting's key decisions, not just an announcement that the minutes are available.
2022-04-21 English
Ultimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical Development
Regulatory Filings Classification · 95% confidence The document is a press release dated April 8, 2022, announcing that Ultimovacs presented pre-clinical data on its TET platform at the AACR 2022 annual meeting. It details scientific findings, mentions an ongoing Phase I trial (TENDU), and states that the abstract is published in the online Proceedings of the AACR. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement about scientific data presentation and publication, which fits best under the general category for regulatory announcements or scientific updates that don't fit other specific categories. Since it is an announcement about scientific data being presented at a conference, and it is not a formal financial report, 'Regulatory Filings' (RNS) serves as the most appropriate general category for this type of corporate communication that is not explicitly defined elsewhere (like ER, CT, or IP). It is not an Investor Presentation (IP) as it is a press release summarizing the presentation, not the presentation itself.
2022-04-08 English
Ultimovacs ASA - Disclosure of voting rights of Annual General Meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly mentions 'Disclosure of voting rights of Annual General Meeting' and details the total voting rights and proxies received by the Chair of the Board in connection with the upcoming AGM. This directly relates to the official results or pre-meeting status of shareholder votes. While it is not the final result (DVA), it is a specific disclosure regarding voting rights related to the AGM. Given the options, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most appropriate fit as it covers announcements related to voting rights for general meetings. The document is short and is a specific disclosure, not a comprehensive report.
2022-04-08 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.